A Phase 3 interventional study of BXCL501 and Matching Placebo in Agitation and Dementia, sponsored by BioXcel Therapeutics Inc. Completed at 11 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,051 studies in Dementia with a site in United States — 213 open to participants now, 278 under way, 15 of them phase 3. Dementia · United States.
Among the 1,051 studies in Dementia with a site in United States, this one is the 318th largest by enrollment of the 847 interventional ones that give a count, is one of 88 that started in 2022, is one of 58 in phase 3, and was the 693rd registered.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
Browse Dementia studies →213 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 50+ · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 21+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,051 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 146 · Phase 3 79 · Phase 4 33
First in 1981; this study’s year is marked. 88 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 93 across the 847 interventional studies, 200 across the 199 observational. Of the 714 that completed or were terminated, 309 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 1,051 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
BioXcel Therapeutics Inc has 4 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
110 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT07859865Drexel UniversityMindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers | 2026-11-30 |
Add all 110 to your calendar (.ics) → With an account.
Among the 1,051 studies in Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses within a 12-week treatment period.
A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female subjects (65 years and older) with acute psychomotor agitation. Subjects will be dosed PRN with a maximum of 28 doses over a 12-week period. Once a subject has received 28 doses of BXCL501, they will continue to be followed for the remainder of the 12-week study period.
Approximately 150 subjects will participate in this study. Subjects will receive a single film consisting of BXCL501 40 µg dose or BXCL501 60 µg dose or placebo in a 1:1:1 randomization scheme. Subjects must reside in a care facility where all study-related procedures and study drug dosing will be performed.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
This study's enrollment of 151 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Browse Dementia studies →BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
Compared within Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sublingual film containing 40 Micrograms Dexmedetomidine
Drug: BXCL501
Sublingual film containing 60 Micrograms Dexmedetomidine
Drug: BXCL501
Sublingual Placebo film
Drug: Matching Placebo
Sublingual Film
Also known as: Dexmedetomidine
Sublingual Placebo Film
Also known as: Placebo
Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time frame: 120 minutes
Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited for the First Episode of Agitation
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time frame: 30 minutes
Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited for the First Episode of Agitation
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time frame: 60 minutes
Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited for All Episodes of Agitation
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time frame: 120 minutes
The study was conducted in United States from 18 April 2022 to 21 April 2023.
| Milestone | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo |
|---|---|---|---|
| Started | 48 | 50 | 53 |
| Completed | 38 | 29 | 32 |
| Not completed | 10 | 21 | 21 |
| Withdrew: Adverse event | 4 | 6 | 3 |
| Withdrew: Death | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 5 | 4 |
| Withdrew: Withdrawal by subject | 0 | 4 | 7 |
| Withdrew: Other medical reason. | 1 | 2 | 0 |
| Withdrew: Other | 3 | 3 | 6 |
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
| score on a scale | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation | -5.7 ± 0.6 | -7.5 ± 0.6 | -5.4 ± 0.6 |
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
| score on a scale | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited for the First Episode of Agitation | -2.5 ± 0.5 | -3.6 ± 0.5 | -3.4 ± 0.5 |
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
| score on a scale | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited for the First Episode of Agitation | -4.2 ± 0.6 | -6.2 ± 0.6 | -4.2 ± 0.6 |
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
| score on a scale | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited for All Episodes of Agitation | -5.8 ± 0.5 | -7.4 ± 0.5 | -5.2 ± 0.5 |
Collected over 24 hours after dose administration (treatment emergent adverse events). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1- 40 Micrograms | 1/48 (2.1%) | 0/48 (0%) | 6/48 (12.5%) |
| Cohort 2- 60 Micrograms | 1/50 (2%) | 0/50 (0%) | 16/50 (32%) |
| Placebo | 1/51 (2%) | 0/51 (0%) | 2/51 (3.9%) |
| Event | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 2/48 | 3/50 | 0/51 |
| HypotensionVascular disorders | 0/48 | 3/50 | 0/51 |
| Orthostatic HypotensionVascular disorders | 2/48 | 2/50 | 0/51 |
| BradycardiaCardiac disorders | 1/48 | 2/50 | 0/51 |
| LethargyNervous system disorders | 1/48 | 1/50 | 0/51 |
| DizzinessNervous system disorders | 0/48 | 1/50 | 1/51 |
| DiarrhoeaGastrointestinal disorders | 0/48 | 1/50 | 0/51 |
| Skin lacerationInjury, poisoning and procedural complications | 0/48 | 1/50 | 0/51 |
| Wrist fractureInjury, poisoning and procedural complications | 0/48 | 1/50 | 0/51 |
| Fracture treatmentSurgical and medical procedures | 0/48 | 1/50 | 0/51 |
The Safety Population includes all subjects who received the study treatment. Two subjects randomized to Placebo voluntarily withdrew before dosed.
| Age, Continuous(Years) | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Mean | 79.4 ± 6.44 | 79.5 ± 8.14 | 80.0 ± 7.48 | 79.6 ± 7.35 |
| Sex: Female, Male(Participants) | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Female | 27 | 30 | 33 | 90 |
| Male | 21 | 20 | 18 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 22 | 19 | 59 |
| Not Hispanic or Latino | 30 | 28 | 32 | 90 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 13 | 5 | 11 | 29 |
| White | 35 | 43 | 39 | 117 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Baseline Positive and Negative Syndrome Scale - Excited Component (PEC)(units on a scale) | Cohort 1- 40 Micrograms | Cohort 2- 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Mean | 17.3 ± 2.18 | 18.0 ± 2.26 | 17.5 ± 2.62 | 17.6 ± 2.36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Apr 2023, 11 months.
Results were first posted in Dec 2025, 2 years 8 months after primary completion. A results delay was requested in Jul 2023.
Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc